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ABSTRACT 25 
 26 
Objectives: Because of the emergence of plasmid-mediated (mcr-1 and mcr-2 genes) and 27 
chromosomally-encoded colistin resistance, reliable methods for detecting colistin 28 
resistance/susceptibility in routine laboratories are required. We evaluated the respective 29 
performances of the BD Phoenix automated system, the newly-developed Rapid Polymyxin 30 
NP test and the broth microdilution (BMD) reference method to detect colistin resistance in 31 
Enterobacteriaceae, and particularly those producing MCR-1 and MCR-2. 32 
Methods: Colistin susceptibility of 123 enterobacterial clinical isolates (40 colistin-33 
susceptible and 83 colistin-resistant isolates) was tested with the Phoenix automated system, 34 
the Rapid Polymyxin NP test and the BMD method. Molecular mechanisms responsible for 35 
plasmid-mediated and chromosomally-encoded colistin resistance mechanisms were 36 
investigated by PCR and sequencing. 37 
Results: Considering BMD as a reference method, the Phoenix system failed to detect ten 38 
colistin-resistant isolates (one Escherichia coli, one Klebsiella pneumoniae, seven 39 
Enterobacter spp., and one Salmonella enterica). The Rapid Polymyxin NP test failed to 40 
detect the same single E. coli isolate. Those two latter methods detected the sixteen E. coli, K. 41 
pneumoniae and S. enterica isolates producing the plasmid-encoded MCR-1 and MCR-2. 42 
Conclusion: The Phoenix system and the Rapid Polymyxin NP test are reliable techniques for 43 
detecting plasmid-mediated MCR-1 and MCR-2-related colistin resistance. However, a high 44 
rate of false susceptibility was observed with the Phoenix system, indicating that 45 
susceptibility results obtained with that system should be confirmed by BMD method. By 46 
contrast, the Rapid Polymyxin NP test showed a good agreement with the BMD method and 47 
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results were obtained rapidly (within two hours). The BMD method should be performed if 48 
MIC values are needed.  49 
  50 
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INTRODUCTION 51 
The increasing use of colistin in human medicine, and the recent discovery of plasmid-52 
mediated polymyxin resistance [1–4], highlight the need for reliable methods for polymyxin 53 
susceptibility testing. 54 
The Clinical Laboratory Standard Institute (CLSI) and the European Committee on 55 
Antimicrobial Susceptibility Testing (EUCAST) recently gathered in a joint subcommittee, 56 
chose the broth microdilution (BMD) method as the reference method (www.eucast.org). It 57 
must be performed with sulfate salts of polymyxins (colistimethate used in human medicine 58 
shall not be used), with cation-adjusted Mueller-Hinton broth, without additive (in particular 59 
without polysorbate 80) and without treated polystyrene trays. Other methods such as, agar 60 
dilution, disk diffusion and gradient diffusion (E-test) have been ruled out. However, this gold 61 
standard BMD method is difficult to performed in routine laboratories since it requires 62 
qualified staff, is time-consuming, and requires manual preparation of antibiotic solutions [5].  63 
Automated dilution methods such as those performed by the BD Phoenix system could 64 
be an alternative for the screening of colistin resistance for laboratories that cannot perform 65 
manual BMD. However, the performance of this automate for colistin susceptibility testing, 66 
especially its accuracy for the detection of isolates exhibiting a plasmid-mediated colistin 67 
resistance, have never been evaluated. Recently, a rapid colorimetric test, the Rapid 68 
Polymyxin NP test, has been developed for detecting polymyxin resistance in 69 
Enterobacteriaceae within 2 hours [6]. 70 
 The objective of this study was to evaluate the performance of the BD Phoenix 71 
automated system to detect plasmid-mediated and chromosomally-encoded colistin resistance, 72 
using a collection of clinical enterobacterial isolates. We also aimed to compare their 73 
performances to those of the Rapid Polymyxin NP test and the BMD reference method. 74 
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MATERIAL AND METHODS 75 
Bacterial strains. This study was carried out using 123 non-duplicated clinical 76 
isolates of various enterobacterial species. The collection included 40 colistin-susceptible and 77 
83 colistin-resistant isolates. Out of the 83 colistin-resistant isolates, sixteen belonged to a 78 
genus known to be naturally-resistant to colistin (Morganella, Proteus, Providencia, Serratia, 79 
Hafnia), and 67 isolates belonged to the Escherichia, Klebsiella, Enterobacter, or Salmonella 80 
genus with acquired resistance mechanisms to colistin. Identification of the isolates at the 81 
species level was performed using the Microflex bench-top MALDI-TOF mass spectrometer 82 
(Brücker, Champs-sur-Marne, France). Isolates were grown on Luria Bertani (LB) 83 
(GibcoBRL, Cergy Pontoise, France) or Mueller Hinton (MH) (bioMérieux, Marcy-l’Etoile, 84 
France) agar plates at 35±2°C for 18 h. The colistin-susceptible E. coli ATCC 25922 strain 85 
was included in all experiments as quality control. 86 
Susceptibility testing 87 
Reference antimicrobial susceptibility testing 88 
The BMD method was performed according to the EUCAST/CLSI joined guidelines 89 
(www.eucast.org). Briefly, BMD panels were prepared extemporaneously in 96-wells sterile 90 
polystyrene microplates (Sarstedt, Nümbrecht, Germany). Dilutions of colistin (Sigma Aldrich, 91 
St Louis, USA) ranging from 0.125 to 128 mg/l were made in cation-adjusted MH broth (Bio-92 
Rad, Marnes-la-Coquette, France), without addition of polysorbate 80 (Tween 80), and with a 93 
final concentration of 5x105 CFU/ml of bacteria in each well. This procedure was performed 94 
in triplicate in separate experiments and the Minimum Inhibitory Concentrations (MICs) were 95 
read after 16 to 20 h of incubation at 35±2°C in ambient air. Results were interpreted 96 
according to the EUCAST breakpoints [7], i.e. isolates with MICs of colistin ≤ 2 mg/l were 97 
categorized as susceptible although those with MICs > 2 mg/l were resistant.  98 
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BD Phoenix automated system 99 
Colistin susceptibility testing was assessed using the Phoenix automated system (BD Phoenix 100 
100, BD Diagnostic systems, Le Pont de Claix, France), which performs automated BMD 101 
method. The panel selected to perform this evaluation was the Gram-negative panel NMIC-102 
93, using the BMD method for colistin concentrations ranging from 0.5 to 4 mg/l in order to 103 
cover the EUCAST breakpoints [7]. The bacterial suspension and the panel inoculation were 104 
performed according to the manufacturer’s guidelines. Panels were incubated up to 16 h at 105 
35±2°C under ambient air, and results were interpreted with the BD EpiCenter software. 106 
Rapid Polymyxin NP test 107 
The Rapid Polymyxin NP test is based on the detection of the glucose metabolism related to 108 
bacterial growth in presence of a fixed concentration of colistin (3.75 mg/l) in cation-adjusted 109 
MH broth medium [6]. Formation of acid metabolites consecutive to the glucose metabolism 110 
is evidenced by a color change (orange to yellow) of the pH indicator (red phenol). The test is 111 
positive (colistin resistance) if a strain grows in presence of colistin, whereas it is negative 112 
(colistin susceptibility) if a strain does not grow in presence of colistin. Results of the Rapid 113 
Polymyxin NP test were read at 2 h of incubation at 35±2°C in ambient air. 114 
Molecular characterization of the colistin resistance. Molecular mechanisms 115 
responsible for plasmid-mediated (mcr-1 and mcr-2 genes) and chromosomally-encoded 116 
(pmrA, pmrB, phoP, phoQ, mgrB, and crrB alterations) colistin resistance were determined as 117 
described previously [1,2,8–12]. 118 
Results analysis. The results obtained with the BD Phoenix system and the Rapid 119 
Polymyxin NP test were compared to those obtained with the reference BMD method. 120 
Discrepancies were determined for each method in order to assess their performance to detect 121 
colistin resistance. For strains for which discrepant susceptibility results were obtained, the 122 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
isolates were retested with the three methods. Unsolved discrepancies were then maintained in 123 
the database for performance evaluation. Errors were ranked as follows: a very major error 124 
(VME) was defined when isolates were categorized as susceptible using the Phoenix system 125 
or the Rapid Polymyxin NP test but resistant by the BMD method (false-susceptible result), 126 
while a major error (ME) was defined when isolates were found resistant using the Phoenix 127 
system or the Rapid Polymyxin NP test, but were found susceptible by using the BMD 128 
method (false-resistant result). The number of resistant isolates, and the number of susceptible 129 
isolates were used as denominators for VME and ME calculations, respectively. Acceptance 130 
criteria that provide requirements, and specifications to evaluate performances of 131 
antimicrobial susceptibility test devices were those defined by the ISO standards (VME and 132 
ME must be ≤3%) [13].  133 
RESULTS 134 
The features of the 123 enterobacterial isolates included in this study to evaluate the 135 
performance of the BD Phoenix system and the Polymyxin NP test for determining colistin 136 
susceptibility are presented in the Table.  137 
Fourty isolates defined as colistin-susceptible according to the results of the BMD 138 
method (MICs of colistin ranging from 0.12 to 2 µg/ml) were found susceptible by the BD 139 
Phoenix system (Table). While a single susceptible K. pneumoniae isolate with an MIC of 140 
colistin at 2 mg/l was found resistant using the Rapid Polymyxin NP test. The MIC value of 141 
colistin for this same isolate as determined by the BD Phoenix system was underestimated 142 
(MIC ≤ 0.5 mg/l) but the isolate was well categorized as susceptible. 143 
Out of the 83 colistin-resistant enterobacterial isolates (MICs of colistin ranging from 144 
4 to higher than 128 mg/l), the Phoenix system failed to detect colistin resistance for seven 145 
Enterobacter spp. isolates, a single K. pneumoniae, a single S. enterica, and a single E. coli 146 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
isolate, whereas the Rapid Polymyxin NP test only failed for detecting a single colistin-147 
resistant E. coli isolate. (Table). Identical results were obtained when those strains were 148 
repeatedly tested with the Phoenix system and the Rapid Polymyxin NP test indicating a good 149 
reproducibility of the methods.  150 
 Noteworthy, thirteen non clonally-related colistin-resistant E. coli, one K. pneumoniae, 151 
and one S. enterica isolate possessing the plasmid-mediated mcr-1 gene were tested (MICs of 152 
colistin ranging from 4 to 64 mg/l using the BMD method) and all were identified as resistant 153 
with the BD Phoenix system and the Rapid Polymyxin NP test. Similarly, the E. coli isolate 154 
possessing the plasmid-mediated mcr-2 gene (MIC = 4 mg/l) was detected by the two 155 
methods.  156 
DISCUSSION 157 
 Out of the 40 colistin-susceptible enterobacterial isolates, no ME (i.e. false resistance) 158 
was found with the Phoenix system, and only a single susceptible K. pneumoniae isolate with 159 
an MIC of colistin at 2 mg/l (therefore just below the EUCAST breakpoint value > 2 mg/l) 160 
was falsely identified as colistin resistant with the Rapid Polymyxin NP test revealing a ME 161 
rate of 2.5%.test 162 
Out of the 83 colistin-resistant enterobacterial isolates, the BD Phoenix system and the 163 
Rapid Polymyxin NP test showed excellent performances to detect the 13 isolates with 164 
plasmid-mediated colistin resistance regardless of the level of resistance. However, ten VME 165 
(i.e. false susceptibility) were found with the Phoenix system whereas a single VME was 166 
found with the Rapid Polymyxin NP test (Table). A high VME rate of 12% was thus found 167 
with the BD Phoenix system, whereas a low VME rate of 1.2% was found with the Rapid 168 
Polymyxin NP test. The single colistin-resistant E. coli isolate that was not detected with the 169 
BD Phoenix system and the Rapid Polymyxin NP test, presented a low level of resistance 170 
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(MIC of colistin at 8 mg/l). Its mechanism of colistin resistance remains unknown (neither 171 
chromosomally-encoded mutations in genes known to be involved in lipopolysaccharide 172 
modifications, i.e. mgrB, pmrAB and phoPQ genes, nor plasmid-mediated mcr-1 and mcr-2 173 
genes were detected).     174 
The S. enterica isolate identified as susceptible (MIC = 2 mg/l) with the BD Phoenix system 175 
presented a low level of colistin resistance (MIC = 4 mg/l) and its mechanism of resistance 176 
remains unknown (neither chromosomal mutations, nor plasmid-mediated resistance). 177 
The K. pneumoniae resistant isolate and the seven Enterobacter spp. resistant isolates not 178 
detected with the BD Phoenix system exhibited MIC values of colistin ranging from 16 to 179 
higher than 128 mg/l and were identified as colistin resistant with the Rapid Polymyxin NP 180 
test. During the determination of MICs by the BMD method, skipped wells (i.e. wells that 181 
exhibit no growth although growth does occur at higher concentrations) were observed for 182 
88% of those isolates (the K. pneumoniae isolate and six Enterobacter spp. isolates). This 183 
observation suggests that the failure of the BD Phoenix system to detect colistin resistance in 184 
those isolates could be related to a heteroresistance phenotype (defined by the presence of two 185 
subpopulations exhibiting different susceptibilities to colistin) [14]. The skipped wells 186 
observed during the MIC determination of those isolates by the BMD method are mainly for 187 
dilutions comprised between 0.125 and 4 mg/l. The Phoenix panel used in this study 188 
contained dilutions of colistin ranging from 0.5 to 4 mg/l. It is therefore likely that the failure 189 
of detection of heteroresistance for those isolates was linked to the absence of testing at higher 190 
colistin concentrations. The low sensitivity to detect colistin heteroresistance has already been 191 
described for another automated system, i.e. the bioMérieux Vitek system [15]. 192 
The limitation of our study could be the absence of testing of non-fermenting Gram negative 193 
rods in our collection. 194 
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CONCLUSION 195 
This study shows that the BD Phoenix system and the Rapid Polymyxin NP test are 196 
reliable tools for detection of plasmid-mediated colistin resistance (mcr-1 and mcr-2 genes), 197 
which is currently a major concern. However, the BD Phoenix system is not reliable for 198 
detection of colistin heteroresistance in enterobacterial isolates. Thus, we recommend the 199 
determination of MICs by the BMD method when susceptible results are obtained and if 200 
clinical use is required. By contrast, the Rapid Polymyxin NP test showed a good agreement 201 
with the BMD method and results were obtained rapidly (within two hours), but BMD 202 
method should be performed if determination of MIC values is necessary.  203 
 204 
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Table. MICs of colistin (mg/l) using the BMD method and the BD Phoenix system and results of the Rapid Polymyxin NP test.  
Isolate Species Phenotype Mechanism of resistance to 
colistina 
BMD Phoenix  Rapid Polymyxin NP test 
 (number of isolates)  MIC colistin MIC colistin Discrepanciesb Result Discrepanciesb,c 
Isolates susceptible to colistin 
ATCC25922 E. coli S NA 0.25 ≤0.5 No - No 
2 to 15 E. coli (n= 14) S NA 0.12 to 0.5 ≤0.5 No - No 
16 to 26 K. pneumoniae 
(n=11) 
S NA 0.12 to 2 ≤0.5 No - Yes, ME (n=1) 
27 to 29 K. oxytoca (n=3) S NA 0.12 to 0.25 ≤0.5 No - No 
30 to 32 E. cloacae (n=3) S NA 0.12 to 0.25 ≤0.5 No - No 
33 E. asburiae S NA 0.12 ≤0.5 No - No 
34 E. aerogenes S NA 0.12 ≤0.5 No - No 
35 to 37 C. freundii (n=3) S NA 0.25 ≤0.5 No - No 
38 to 40 C. koseri (n=3) S NA 0.12 to 0.25 ≤0.5 No - No 
Isolates resistant to colistin 
41 M. morganii R Intrinsic >128 >4 No + No 
42-43 P. mirabilis (n=2) R Intrinsic >128 >4 No + No 
44 P. vulgaris R Intrinsic >128 >4 No + No 
45 P. stuartii R Intrinsic >128 >4 No + No 
46 to 48 S. marcescens (n=3) R Intrinsic >128 >4 No + No 
49 to 52 H. alvei (n=4) R Intrinsic 8 or 16 4 or >4 No + No 
53 to 56 H. paralvei (n=4) R Intrinsic 8 4 or >4 No + No 
57 to 68 E. coli (n= 11) R Plasmid-mediated mcr-1 gene 4 or 8 4 or >4 No + No 
69 E. coli R Plasmid-mediated mcr-1 gene 64 >4 No + No 
70 E. coli R Plasmid-mediated mcr-2 gene 4 4 No + No 
71 K. oxytoca R ISKpn26 into mgrB promotor 64 >4 No + No 
72 E. coli R Unknown 8 ≤0.5 Yes, VME - Yes, VME 
73 E. coli R Unknown 8 >4 No + No 
74 E. coli R Unknown 4 4 No + No 
75 E. coli R Unknown 16 >4 No + No 
76 K. pneumoniae R PmrA G53C 64 >4 No + No 
77-78 K. pneumoniae (n=2) R PmrA G53S 16 or 32 >4 No + No 
79-80 K. pneumoniae (n=2) R PmrB T157P 16 or 32 >4 No + No 
81 K. pneumoniae R PhoP D191Y 128 ≤0.5 Yes, VME + No 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
82 K. pneumoniae R PhoQ R16C 128 >4 No + No 
83 K. pneumoniae R MgrB N42Y et K43I  64 >4 No + No 
84 K. pneumoniae R MgrB I45T 64 >4 No + No 
85 to 87 K. pneumoniae (n=3) R MgrB truncated 64 or 128 >4 No + No 
88 K. pneumoniae R Deletion of 11 nucleotides into 
mgrB gene 
>128 >4 No + No 
89 K. pneumoniae R blaCTX-M-15/ISEcp1 into mgrB 64 >4 No + No 
90 K. pneumoniae R IS5 into mgrB gene 64 >4 No + No 
91 K. pneumoniae R IS102 into mgrB gene >128 >4 No + No 
92 K. pneumoniae R ISKpn14 into mgrB gene 32 >4 No + No 
93 K. pneumoniae R ISKpn13 into mgrB gene 128 >4 No + No 
94 K. pneumoniae R ISKpn26 into mgrB gene 64 >4 No + No 
95 K. pneumoniae R IS903 into mgrB gene 128 >4 No + No 
96 K. pneumoniae R IS903b into mgrB gene 64 >4 No + No 
97 K. pneumoniae R IS5 into mgrB gene 128 >4 No + No 
98 K. pneumoniae R IS10R into mgrB promotor 128 >4 No + No 
99 K. pneumoniae R ISKpn14 into mgrB promotor 32 >4 No + No 
100 K. pneumoniae R CrrB N141Y  >128 >4 No + No 
101 K. pneumoniae R CrrB P151L >128 >4 No + No 
102 K. pneumoniae R CrrB G183V >128 >4 No + No 
103 K. pneumoniae R Plasmid mediated mcr-1 gene 16 4 No + No 
104 K. pneumoniae R Unknown 16 >4 No + No 
105 K. pneumoniae R Unknown 64 >4 No + No 
106 K. pneumoniae R Unknown 32 >4 No + No 
107 K. pneumoniae R Unknown >128 >4 No + No 
108 K. pneumoniae R Unknown 64 >4 No + No 
109 K. pneumoniae R Unknown 64 >4 No + No 
110 K. pneumoniae R Unknown 32 >4 No + No 
111 E. cloacae R Unknown 32 >4 No + No 
112 E. cloacae R Unknown >128 >4 No + No 
113 E. cloacae R Unknown 32 >4 No + No 
114 E. cloacae R Unknown >128 1 Yes, VME + No 
115 E. cloacae R Unknown 64 ≤0.5 Yes, VME + No 
116 E. cloacae R Unknown >128 ≤0.5 Yes, VME + No 
117 E. cloacae R Unknown 16 ≤0.5 Yes, VME + No 
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118 E. cloacae R Unknown >128 ≤0.5 Yes, VME + No 
119 E. cloacae R Unknown >128 ≤0.5 Yes, VME + No 
120 E. asburiae R Unknown >128 ≤0.5 Yes, VME + No 
121 S. enterica R Plasmid mediated mcr-1 gene 16 >4 No + No 
122 S. enterica R Unknown 4 2 Yes, VME + No 
123 S. enterica R Unknown 4 >4 No + No 
S, susceptible; R, resistant; NA, not applicable. 
aUnknown : no mutation in genes known to be involved in colistin resistance (pmrA, pmrB, phoP, phoQ, mgrB and crrB genes) 
bVME, very major error (false-susceptibility compared to the results obtained by broth microdilution reference method) 
cME, major error (false-resistance compared to the results obtained by broth microdilution reference method) 
 
